NMRA Stock Forecast & Price Target

Neumora Therapeutics is a clinical-stage biopharmaceutical company with an innovative approach to developing treatments for brain diseases. Its diversified pipeline of seven clinical and preclinical programs targeting underserved neuropsychiatric disorders and neurodegenerative diseases positions the company for potential success in multiple markets. Upcoming catalysts, such as the Phase II study for NMRA-511 and the Navacaprant pivotal readout, hold potential for significant valuation swing events and could drive re-rating for the company. Despite a recent market overreaction to AE findings in its NMRA-215 program, management remains confident and has taken proactive steps to address the issue, including repeating the 13-week rat tox study with a different CRO. Overall, with a strong cash runway, potential for multiple first or best-in-class treatments, and a broad market potential, Neumora is viewed favorably by analysts and has a Buy rating with a $14 price target.

Neumora Therapeutics is facing significant financial challenges as evidenced by their 4Q25 net loss of $59.5MM and a spend rate that is projected to last only until 3Q27. Additionally, their pipeline of seven neuroscience programs targeting underserved diseases may not be enough to generate significant revenue, with the only potential blockbuster being Navacaprant for BPD, with projected US sales of $250M in 2030. Furthermore, their lead candidate for schizophrenia, NMRA-898, has only shown initial encouraging Phase 1 data and may face significant competition in the market.